期刊
CLINICAL THERAPEUTICS
卷 34, 期 8, 页码 1696-1704出版社
ELSEVIER
DOI: 10.1016/j.clinthera.2012.06.025
关键词
cancer; drug interactions; oral anticancer agents; prescriptions; prevalence
资金
- National Medical Research Council [NIG09may028]
- Department of Pharmacy, National University of Singapore
Background: There has been a recent increase in the availability and use of oral anticancer agents (OAAs). Drug drug interactions (DDIs) involving OAAs pose a major concern in oncology practice due to these drugs' narrow therapeutic indices and potential for compromised efficacy and fatal adverse events. Objective: To assess the prevalence of the coprescription of potentially interacting drug combinations involving OAAs in Singapore. Methods: A retrospective review of physicians' electronic prescription records between the years 2007 and 2009 was performed in the largest cancer center in Singapore. An overall prevalence rate of potential DDIs and a prevalence rate for each individual DDI pair were calculated. Logistic regression was used to identify risk factors for potential DDIs. Results: Fifty-eight clinically significant DDIs were selected for evaluation from Drug Interaction Facts and Micromedex DrugDex. A total of 39,772 OAA prescriptions prescribed to 8837 patients were reviewed. Potential DDI coprescription was found in 5.4% of the patients on OAAs and in 4.7% of the OAA prescriptions. The drug pair prescribed to the largest number of patients was prednisolone and aspirin. About half (53.3%) of the observed DDIs were found on the same prescription. On multivariate analysis, older patients, males, and those taking prednisolone had a higher risk for potential DDIs. Conclusion: Although limited by the data available, the analysis of prescription records found that similar to 5% of patients taking OAAs in Singapore were exposed to >= 1 potentially interacting drug combination. (Clin Ther. 2012;34:1696-1704) (C) 2012 Elsevier HS Journals, Inc. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据